Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials.
about
Oral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challengesFacilitators of adherence to the study pill in the FEM-PrEP clinical trialEnding the pandemic: reducing new HIV infections to zeroDisclosure of pharmacokinetic drug results to understand nonadherenceSexual Relationships Outside Primary Partnerships and Abstinence Are Associated With Lower Adherence and Adherence Gaps: Data From the Partners PrEP Ancillary Adherence Study.Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.Global HIV epidemiology: A guide for strategies in prevention and care.FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis.Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence.Helping our patients take HIV pre-exposure prophylaxis (PrEP): a systematic review of adherence interventions.Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.An interdisciplinary framework for measuring and supporting adherence in HIV prevention trials of ARV-based vaginal ringsPassing the baton: Community-based ethnography to design a randomized clinical trial on the effectiveness of oral pre-exposure prophylaxis for HIV prevention among Black men who have sex with men.Medication adherence among men who have sex with men at risk for HIV infection in the United States: implications for pre-exposure prophylaxis implementation.Tailored combination prevention packages and PrEP for young key populations.Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials.Lay Social Resources for Support of Adherence to Antiretroviral Prophylaxis for HIV Prevention Among Serodiscordant Couples in sub-Saharan Africa: A Qualitative Study.Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya.Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial.Sustained High HIV Incidence in Young Women in Southern Africa: Social, Behavioral, and Structural Factors and Emerging Intervention ApproachesPharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.Repeated Vaginal SHIV Challenges in Macaques Receiving Oral or Topical Preexposure Prophylaxis Induce Virus-Specific T-Cell Responses.Optimizing adherence to preexposure and postexposure prophylaxis: the need for an integrated biobehavioral approach.HIV prevention and research considerations for women in sub-Saharan Africa: moving toward biobehavioral prevention strategiesThe promise and peril of pre-exposure prophylaxis (PrEP): using social science to inform prep interventions among female sex workersAn intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate.Planning ahead for implementation of long-acting HIV prevention: challenges and opportunities.An intravaginal ring for real-time evaluation of adherence to therapyTenofovir-based oral preexposure prophylaxis prevents HIV infection among women.Controlling the hydration rate of a hydrophilic matrix in the core of an intravaginal ring determines antiretroviral releaseCombination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine ModelA Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure ProphylaxisPreventing HIV among young people: research priorities for the futureAdherence and the Lie in a HIV Prevention Clinical Trial.Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges.Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary propertiesAdherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection.Parenting Among Adolescents and Young Adults with Human Immunodeficiency Virus Infection in the United States: Challenges, Unmet Needs, and OpportunitiesAssessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: results of a nested case-control study.Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques.
P2860
Q27023352-B7B5AB5B-3E75-41E8-932E-B42CDD14679DQ28546083-AEF547A7-F71E-442D-96BE-096A89FAB562Q30356525-D98C5B29-EC9E-46EA-A2A1-24EAECBA0D61Q30674432-D2BF1920-3C90-4984-849F-C35816FE1CEBQ30944686-7A51D105-E4BE-41E0-9D91-11212D86FB6FQ33570985-6759EF3A-9541-48A0-9BBC-8252FC2F811CQ33703135-C63710EE-57F8-4D52-A076-B61BE3157FCEQ33762990-455AF113-9D2C-4857-962F-A8939902D2A9Q33765789-CE847B47-D697-40EB-8CBE-47B9EF6F42C9Q33934337-7541F45A-8936-4044-BB7A-C286C3014CFEQ34057568-63E42AD7-262B-48F0-B0C2-4FA323A58F58Q34180658-6D0A30C5-36C8-462A-AF50-CA23B5B1660FQ34498357-942E097B-DFD0-4159-9378-78035F5E49DDQ34606560-D9DE2E83-481C-4F8F-A7B8-571B2EE4E839Q35131207-D2D6E1E8-0CAD-4C71-9C11-AEB23EE0ABB7Q35558205-8461B4CE-1BF5-4199-9F25-2DDA3F7E7614Q35558214-6B9E64BF-9747-4C5B-820D-1BF3640AF8EEQ35558232-28AFEEFE-4D6B-4350-978A-C4AC11C0B3EAQ35561492-6E768FCA-9A6C-4617-A2C8-7BC0BC5958C0Q35602771-24B04F96-8277-48AA-B5E4-0697A29F59E5Q35746114-90A3650F-B7D6-4382-913A-A3AE12229170Q35798274-D3C55CB5-60BD-4A19-A76B-75F46A24B301Q35999949-A31A76B2-9A61-4B7E-AFCD-E0D5DF614D5AQ36122114-0CBE135C-F3D4-498D-91AF-CE12F5A008CEQ36160177-892B1C59-AA34-4AF4-8A60-1402EAB9BF81Q36173759-C24543E9-9872-4127-9CC2-DC0BB958C112Q36204808-3D8F6297-EF42-4742-A799-30556A13588EQ36337967-F2C8B81A-1C57-40B3-95E6-653A1B935DC1Q36443803-6C153D90-EB1C-4B5C-84F4-590673AA28C4Q36666807-8EFA391C-45CF-4072-967D-290B6D2AA59CQ36933498-0B0374DF-E3EB-47A3-B467-592F1500721CQ36968405-4925DFF9-02FE-43C2-B964-EE202C3A8686Q37103722-1B248C00-F582-4617-8D6A-4D1C4A15CFDAQ37159067-3C7E5BB5-A451-4A4A-9F83-D86E57A1AE5DQ37218578-FBA9FDA7-C69E-40CD-BEA8-45344507C59AQ37308347-876C9933-9CE2-4426-84A4-53B0897EAEAEQ37626085-5CBFC15F-6DA9-4174-9F5D-8DC548B6E1E7Q37679111-CC49E560-CEA5-4D17-8063-C5FBBB45316DQ37699140-D5170270-8B85-4CB5-8171-E436BA7301D7Q37713043-D1784053-E436-4F43-8112-153D949246FC
P2860
Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Adherence support approaches i ...... r multisite prevention trials.
@en
type
label
Adherence support approaches i ...... r multisite prevention trials.
@en
prefLabel
Adherence support approaches i ...... r multisite prevention trials.
@en
P2093
P2860
P921
P1433
P1476
Adherence support approaches i ...... r multisite prevention trials.
@en
P2093
Amy Corneli
Ariane van der Straten
Kristine Torjesen
Leila E Mansoor
P2860
P2888
P304
P356
10.1007/S10461-013-0429-9
P577
2013-07-01T00:00:00Z